The market has climbed 3.5% in the last 7 days and is up 20% over the past year, with earnings forecasted to grow by 17% annually. In such a robust market, identifying stocks with strong financial foundations can be key to unlocking potential growth. While penny stocks may seem like a term from a bygone era, they continue to offer opportunities for investment in smaller or newer companies that show promise beyond their price point.

Let's take a closer look at a couple of our picks from the screened companies.

SkinHealth Systems (SKIN)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: SkinHealth Systems Inc. is a global medical aesthetics company offering an integrated ecosystem of clinically proven solutions across various regions, with a market cap of $91.39 million.

Operations: The company's revenue comes from its Personal Products segment, which generated $296.12 million.

Market Cap: $91.39M

SkinHealth Systems Inc. is navigating financial challenges with recent quarterly sales of US$72.1 million, down from US$78.2 million the previous year, and a net loss of US$2.7 million compared to a prior net income of US$19.7 million. Despite its unprofitability, the company has managed to reduce losses over five years by 46.4% annually and maintains a cash runway exceeding three years due to positive free cash flow growth. However, it faces delisting risks on Nasdaq unless it meets the minimum bid price requirement by November 2026 while also benefiting from FDA clearance for its SkinStylus microneedling device expansion into new indications.

E.W. Scripps (SSP)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: The E.W. Scripps Company operates as a media enterprise with a portfolio of local television stations and national news and entertainment networks in the United States, with a market cap of approximately $262.72 million.

Operations: The company's revenue is derived from its Local Media segment, which generated $1.36 billion, and the Scripps Networks segment, contributing $782.24 million.

Market Cap: $262.72M

E.W. Scripps is currently unprofitable, with significant challenges highlighted by a recent net loss of US$1.15 billion for Q2 2026, exacerbated by impairments of goodwill and other intangible assets totaling US$1.14 billion. Despite this, the company has secured key retransmission agreements with DIRECTV, restoring service to over 40 markets after a blackout period and enhancing its distribution footprint. Its high net debt to equity ratio of 197.9% remains concerning; however, it maintains a positive cash flow runway exceeding three years. The management team's experience could be pivotal in navigating these financial hurdles moving forward.

Vaso (VASO)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Vaso Corporation, along with its subsidiaries, operates in the healthcare equipment and information technology sectors both in the United States and internationally, with a market cap of $44.35 million.

Operations: The company's revenue is derived from three main segments: IT generating $41.71 million, Equipment contributing $2.56 million, and Professional Sales Service bringing in $44.72 million.

Market Cap: $44.35M

Vaso Corporation's recent performance highlights both opportunities and challenges typical of penny stocks. The company reported a slight decline in quarterly revenue to US$19.36 million, while managing to reduce its net loss compared to the previous year. Despite Vaso's earnings growth of 67.5% over the past year, its five-year earnings trend remains negative at -22.9% annually. The FDA's warning about product marketing claims could impact operations, but the appointment of Shaun McMeans as a director may strengthen financial oversight given his extensive experience in financial management roles across various companies.

Where To Now?

• Explore the 325 names from our US Penny Stocks screener here.
• Interested In Other Possibilities? Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.